These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 30698488

  • 1. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
    De La Fuente J, Hernandez Aguado JJ, San Martín M, Ramirez Boix P, Cedillo Gómez S, López N.
    Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
    [Abstract] [Full Text] [Related]

  • 2. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
    Cody P, Tobe K, Abe M, Elbasha EH.
    BMC Infect Dis; 2021 Jan 06; 21(1):11. PubMed ID: 33407188
    [Abstract] [Full Text] [Related]

  • 3. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
    Tay SK, Hsu TY, Pavelyev A, Walia A, Kulkarni AS.
    BJOG; 2018 Mar 06; 125(4):478-486. PubMed ID: 29266694
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-Effectiveness of 9-Valent HPV Vaccination for Patients Treated for High-Grade Cervical Intraepithelial Neoplasia in the UK.
    Cherif A, Ovcinnikova O, Palmer C, Engelbrecht K, Reuschenbach M, Daniels V.
    JAMA Netw Open; 2024 Oct 01; 7(10):e2437703. PubMed ID: 39365579
    [Abstract] [Full Text] [Related]

  • 7. The impact and cost-effectiveness of nonavalent HPV vaccination in the United States: Estimates from a simplified transmission model.
    Chesson HW, Markowitz LE, Hariri S, Ekwueme DU, Saraiya M.
    Hum Vaccin Immunother; 2016 Jun 02; 12(6):1363-72. PubMed ID: 26890978
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cost-effectiveness and epidemiological impact of gender-neutral HPV vaccination in Spain.
    Linertová R, Guirado-Fuentes C, Mar-Medina J, Teljeur C.
    Hum Vaccin Immunother; 2022 Nov 30; 18(6):2127983. PubMed ID: 36347243
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
    Chou HH, Chang SC, Sukarom I, Saxena K, Pavelyev A, Wu YH, Chang CJ.
    Value Health Reg Issues; 2022 Nov 30; 32():79-87. PubMed ID: 36116338
    [Abstract] [Full Text] [Related]

  • 16. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C, Brotherton JM, Pillsbury A, Jayasinghe S, Donovan B, Macartney K, Marshall H.
    Euro Surveill; 2018 Oct 30; 23(41):. PubMed ID: 30326995
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.